Scott Kellen
2023
In 2023, Scott Kellen earned a total compensation of $632.2K as Chief Financial Officer and Secretary at DiaMedica Therapeutics, a 12% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $116,025 |
|---|---|
| Option Awards | $146,790 |
| Salary | $352,750 |
| Other | $16,650 |
| Total | $632,215 |
Kellen received $352.8K in salary, accounting for 56% of the total pay in 2023.
Kellen also received $116K in non-equity incentive plan, $146.8K in option awards and $16.7K in other compensation.
Rankings
In 2023, Scott Kellen's compensation ranked 1,731st out of 2,918 executives tracked by ExecPay. In other words, Kellen earned more than 40.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,731 out of 2,918 | 41st |
Division Manufacturing | 1,008 out of 1,608 | 37th |
Major group Chemicals And Allied Products | 635 out of 901 | 30th |
Industry group Drugs | 619 out of 864 | 28th |
Industry Pharmaceutical Preparations | 442 out of 622 | 29th |
Source: SEC filing on April 4, 2024.
Kellen's colleagues
We found three more compensation records of executives who worked with Scott Kellen at DiaMedica Therapeutics in 2023.
News
DiaMedica Therapeutics CEO Rick Pauls' 2023 pay rises 12% to $1.2M
April 4, 2024
DiaMedica Therapeutics CEO Rick Pauls' 2022 pay slips 5% to $1.1M
April 4, 2023
DiaMedica Therapeutics CEO Rick Pauls' 2021 pay jumps 29% to $1.1M
April 5, 2022
DiaMedica Therapeutics CEO Rick Pauls' 2019 pay jumps 105% to $1.5M
April 20, 2020
DiaMedica Therapeutics CEO Rick Pauls' 2018 pay jumps 46% to $734K
April 8, 2019